Safety

Aggrenox (aspirin/extended release dipyridamole) 25 mg/200 mg Capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

November 2015

Summary View

WARNINGS AND PRECAUTIONS

Risk of Bleeding
  • Risk factors for bleeding include the use of other drugs that increase the risk of bleeding e.g. anagrelide

DRUG INTERACTIONS

Drug Interaction Study Information Obtained From Literature
  • Anagrelide: Patients taking aspirin in combination with anagrelide are at an increased risk of bleeding.

 

September 2012

Summary View

5 WARNINGS AND PRECAUTIONS

5.1 Risk of Bleeding
  • AGGRENOX increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anti-platelet agents, anticoagulants heparin, fibrinolytic therapy, and chronic use of NSAIDs) [see Drug Interactions (7.1)]

7 DRUG INTERACTIONS

7.1 Drug Interaction Study Information Obtained From Literature
  • Co-administration with anti-coagulants, anti-platelets, or NSAIDS can increase risk of bleeding

 

Page Last Updated: 12/11/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.